Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract.
Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract.
复制标题
用于向呼吸道输送治疗剂和诊断剂的气雾剂。
DOI：
--
复制
发表时间：
1990
影响因子：
2.7
通讯作者：
I. Gonda
中科院分区：
文献类型：
--
作者：
I. Gonda
吸入治疗和诊断气雾剂是靶向给药系统的例子：它们在呼吸道(这些系统通常的靶器官)中达到高浓度，而在人体其他部位出现低浓度。开发和使用吸入性气雾剂需要了解这些动态系统的特性以及它们与解剖和病理生理复杂的人类呼吸道相互作用的方式。最初沉积在呼吸道不同部位的气溶胶颗粒或液滴的数量将决定局部影响的强度以及这些物质从呼吸道管腔中清除的速度。这一活性可以通过适当的配方干预来调节，例如以缓释形式的载体呈现活化剂。通过这种方式延长吸入性药物的作用期限是可能的。随着对受体定位和跟踪吸入药物及其载体命运的更多辨别方法的出现，通过直接给药到呼吸道来改善用于肺部治疗的药物的选择性毒性的最终潜力可以进行批判性评估。
Inhaled therapeutic and diagnostic aerosols are examples of targeted delivery systems: they achieve high concentration in the respiratory tract (the usual target organ with these systems) while appearing in low concentrations in other parts of the human body. Development and use of inhalation aerosols requires an appreciation of the properties of these dynamic systems and the ways in which they interact with the anatomically and pathophysiologically complex human respiratory tract. The amounts of aerosol particles, or droplets, initially deposited at various sites in the respiratory tract will determine the intensity of local effects as well as the rate of clearance of these materials from the respiratory lumen. This activity can be modulated by suitable formulation intervention, such as presentation of the active agent in a slow releasing form carrier. Extension of duration of action of inhaled drugs by such means could be possible. As more discriminating methods for location of receptors and for the following of the fate of inhaled drugs and their carriers are becoming available, the ultimate potential for improvement of selective toxicity of agents used in pulmonary therapy by direct delivery into the respiratory tract can be critically evaluated.